Where does Remd Biotherapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Remd Biotherapeutics, Inc. ranks #25,077 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Remd Biotherapeutics, Inc. hold?

Remd Biotherapeutics, Inc. holds 11 US utility patents granted between 2020 and 2023, spanning 3 technology areas.

What is Remd Biotherapeutics, Inc.'s Innovation Score?

Remd Biotherapeutics, Inc. has an Innovation Score of 40.5 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Remd Biotherapeutics, Inc. focus on?

Remd Biotherapeutics, Inc.'s top technology area is C07K (Peptides) with 11 patents, ranking #825 of 3,615 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Remd Biotherapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Remd Biotherapeutics, Inc..

What does claim depth mean for Remd Biotherapeutics, Inc.'s patents?

Remd Biotherapeutics, Inc.'s patents average 13.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Remd Biotherapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Remd Biotherapeutics, Inc.

USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, recorded in grant years 2020–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Remd ranks #25,077 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 3 technology areas.

#25,077
of 49,997 US assignees by volume: Top 36%
by Innovation Score (40.5/100): 13.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25077 · US Corporation #25,077 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 11 grants
MID-PACK #25,077/49,997
PHOTO-FINISH Rapa Automotive & KG
CPC-NARROW C07K · 3 areas
INNOV-PAR 40.5/100
CLAIMS-RICH 13.3 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2023 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Rapa Automotive GmbH & Co. KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Remd’s 40.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (21%) Velocity 17.8 pts (44%) Breadth 6.1 pts (15%) Claim depth 8.0 pts (20%)

Qualcomm Incorporated · highest

85
Remd Biotherapeutics · this assignee

40
3D Lighting… · lowest

7

What this shows Remd's Innovation Score is 40.5/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Remd?

Each dot is one of Remd’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Remd’s own 13.3 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Remd vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Remd's grants concentrate

Remd Biotherapeutics, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (7 grants) versus a trough of 1 in 2023. By volume, Remd sits between Rapa Automotive GmbH & Co. KG and RF Elements SRO.

Remd's three-year grant acceleration

Remd Biotherapeutics, Inc. shows 8 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Rapa Automotive &…

11
Realta Holdings

11
REM Technology

11
Remacro Technology

11
Repro-med Systems

11
Republic Brands

11
Retrax Holdings

11
RF Elements SRO

11
Remd Biotherapeut… ◀

11

What this shows Remd holds 11 patents at rank #25,049, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Remd

By rank, the assignees closest to #25,049 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Remd's primary technology class.

Remd's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Remd Biotherapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	3	27.3%
2022	7	63.6%
2023	1	9.1%

Which technologies does Remd Biotherapeutics, Inc. patent most?

C07K - Peptides 11

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Remd Biotherapeutics, Inc.'s patent record in context - here's where to go next.

Remd Biotherapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #25,077 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Remd Biotherapeutics, Inc. against Rapa Automotive GmbH & Co. KG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.